NDC 0003-7125

OPDUALAG

Nivolumab And Relatlimab-rmbw

OPDUALAG is a Intravenous Injection in the Human Prescription Drug category. It is labeled and distributed by E.r. Squibb & Sons, L.l.c.. The primary component is Nivolumab; Relatlimab.

• Product ID: 0003-7125_b22c9d83-3256-4e17-85f7-f331a504adc6
• NDC: 0003-7125
• Product Type: Human Prescription Drug
• Proprietary Name: OPDUALAG
• Generic Name: Nivolumab And Relatlimab-rmbw
• Dosage Form: Injection
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2022-03-18
• Marketing Category: BLA /
• Application Number: BLA761234
• Labeler Name: E.R. Squibb & Sons, L.L.C.
• Substance Name: NIVOLUMAB; RELATLIMAB
• Active Ingredient Strength: 12 mg/mL; mg/mL
• Pharm Classes: Programmed Death Receptor-1 Blocking Antibody [EPC], Programmed Death Receptor-1-directed Antibody Interactions [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2023-12-31

Packaging

NDC 0003-7125-11

1 VIAL, SINGLE-DOSE in 1 CARTON (0003-7125-11) > 20 mL in 1 VIAL, SINGLE-DOSE

• Marketing Start Date: 2022-03-18
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details